CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia

This study tests a CAR-T cell therapy targeting CD33 — a protein on leukemia cells — in patients with acute myeloid leukemia (AML) that has come back or stopped responding to standard treatments. CAR-T therapy uses genetically engineered immune cells to seek out and destroy cancer cells. **You may be eligible if...** - You have relapsed or refractory acute myeloid leukemia (AML) - Your leukemia cells express the CD33 protein - You are willing to have tumor tissue used for research - You are in adequate health to receive the experimental therapy - You meet specific blood count and organ function requirements **You may NOT be eligible if...** - Your cancer does not express CD33 - You have severe organ dysfunction (liver, kidney, heart) - You have an uncontrolled active infection - You have received certain prior therapies that would exclude participation Talk to your doctor to see if this trial is right for you.